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Abstract
Cervical cancer cells exhibit an increased requirement for ubiquitin-dependent protein degradation associated with an
elevated metabolic turnover rate, and for specific signaling pathways, notably HPV E6-targeted degradation of p53 and PDZ
proteins. Natural compounds with antioxidant properties including flavonoids and triterpenoids hold promise as anticancer
agents by interfering with ubiquitin-dependent protein degradation. An increasing body of evidence indicates that their a-b
unsaturated carbonyl system is the molecular determinant for inhibition of ubiquitin-mediated protein degradation up-
stream of the catalytic sites of the 20S proteasome. Herein we report the identification and characterization of a new class of
chalcone-based, potent and cell permeable chemical inhibitors of ubiquitin-dependent protein degradation, and a lead
compound RAMB1. RAMB1 inhibits ubiquitin-dependent protein degradation without compromising the catalytic activities
of the 20S proteasome, a mechanism distinct from that of Bortezomib. Treatment of cervical cancer cells with RAMB1
triggers unfolded protein responses, including aggresome formation and Hsp90 stabilization, and increases p53 steady state
levels. RAMB1 treatment results in activation of lysosomal-dependent degradation pathways as a mechanism to
compensate for increasing levels of poly-ubiquitin enriched toxic aggregates. Importantly, RAMB1 synergistically triggers
cell death of cervical cancer cells when combined with the lysosome inhibitor Chloroquine.
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Introduction
Ubiquitin-dependent protein degradation via the ubiquitin-
proteasome system (UPS) is crucial for the regulation of many
cellular processes including cell cycle progression, differentiation
and apoptosis in both normal and cancer cells [1]. Aberrant
expression of components of the UPS system including ubiquitin-
ligases, de-ubiquitinating enzymes and proteasomes has been
reported in several cancer settings including cervical cancer
[1,2,3], suggesting that in order to sustain their higher levels of
metabolic activity cancer cells rely more heavily upon the proper
function of the UPS as compared to their normal counterpart
[4,5,6,7]. Thus, molecules capable of interfering with ubiquitin-
dependent protein degradation, including Bortezomib, show
anticancer activity [5]. Human Papillomavirus (HPV) is the
primary cause of cervical cancer and responsible for 5% of all
cancers worldwide [8]. While HPV vaccines can be an effective
preventive measure against cervical cancer, there are currently no
virus-specific therapies for it, and the efficacy of standard surgical
and chemo/radiotherapies is limited for advanced disease [9].
Expression of two viral oncogenes, E6 and E7, is necessary for the
induction and maintenance of the transformed phenotype [10].
The E6 oncoprotein exerts its oncogenic activity by binding to the
E3 ubiquitin ligase E6-AP and redirects its activity towards p53
and other tumor suppressor proteins for their rapid ubiquitin-
mediated proteasomal degradation [11,12,13]. This reduces the
level of this key cellular cell cycle regulator without its mutation.
Therefore, we hypothesized that stabilization of p53 via
preventing its ubiquitin-mediated degradation will have therapeu-
tic potential for cervical cancer and possibly for other cancers wild-
type for p53.
Natural compounds of the flavonoid and triterpenoids families
including curcumin, Celastrol, green tea polyphenols and
chalcones have shown promise as antineoplastic agents in a
variety of cancer settings including cervical [14], colon [15,16],
oesophageal [17], pancreatic [18] and prostate [19,20,21] cancer,
linked to pro-apoptotic properties as associated with proteasomal
inhibition. We have recently shown that chalcone-derivatives
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proteasome inhibitors and that the nature of the aminoacidic
portion determines their selectivity toward the different catalytic
activities of the 20S proteasome [14]. However other findings
suggest that chalcone molecules might contain within their a-
unsaturated carbonyl system the molecular determinant for
inhibition of ubiquitin-mediated protein degradation upstream of
the 20S proteasome [22,23,24,25].
We report for the first time that a series of chalcone-derivatives
lacking aminoacidic components, here termed RAMBs, are
ubiquitin-proteasome system (UPS)-stressors via inhibition of
ubiquitin-mediated protein degradation upstream of the 20S
proteasomal catalytic activites. Specifically, our RAMBs com-
pounds are capable of selective killing of cervical cancer cells via
accumulation of poly-ubiquitinated protein followed by triggering
of unfolded protein responses including aggresome formation and
Hsp90 stabilization. Further, this accumulation of poly-ubiquiti-
nated proteins is accompanied by a compensatory activation of
lysosome-dependent protein degradation, stabilization of p53, the
destabilization of cyclin D1 and the onset of apoptosis. Our
findings suggest that treatment RAMB compound, possibly
combined with the lysosome inhibitor Chloroquine, has promise
as new avenue for the treatment of cervical cancer.
Materials and Methods
Cell culture
Cervical cancer cell lines HeLa, SiHa, CaSki and ME180, were
obtained from American Type Culture Collection (Manassas, VA)
and cultured in DMEM supplemented with 10% fetal bovine
serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin at
5% CO2. Keratinocytes were obtained from Invitrogen (Carlsbad,
CA) and cultured in defined Keratinocyte-SFM.
Cell viability assay
Cell viability was determined by 2,3-bis[2-methoxy-4-nitro- 5-
sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT)
assay (Roche Diagnostics GmbH, Mannheim, Germany). Cells
seeded at the concentration of 1,000 per well in 100 mL medium in
96-well plate were treated with chalcone-based derivatives at
specified concentrations. After the indicated periods, the cells were
incubated according to the manufacturer’s protocol with the XTT
labeling mixture for 4 hours. Formazan dye was quantified using a
spectrophotometric plate reader to measure the absorbance at
450 nm (ELISA reader 190; Molecular Devices, Sunnyvale, CA).
All experiments were done in triplicate.
Determination of apoptotic cells by flow cytometry
Induction of apoptosis was determined by Annexin-V/7-AAD
staining. Annexin-V/7-AAD staining was done using Annexin V-
PE Apoptosis Detection Kit I (BD Pharmingen, San Diego, CA)
according to manufacturer’s protocol. Briefly, 1610
5 cells were re-
suspended in Binding Buffer, 5 ml of Annexin V-PE and 5 mlo f7 -
AAD were then added into the cells which were then incubated at
room temperature for 15 minutes, and analyzed by flow cytometry
on a Becton Dickinson FACSCalibur. Data analysis was done with
CellQuest software (Becton Dickinson Immunocytometry System,
Mountain View, CA).
Antibodies and Western Blot Analysis
Total cellularprotein (10–20 mg) from each sample was separated
by SDS-PAGE, transferred to PVDF membranes and subjected to
Western blot analysis. Antibodies for Western Blot analysis were
obtained by the following commercial sources: anti-ubiquitin (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-p53 clone DO-1
(Calbiochem, Gibbstown, NJ) anti-PARP (BD Pharmingen, San
Diego, California), anti-GAPDH (Sigma, St. Louis, MO), peroxi-
dase-linked anti-mouse Immunoglobulin G (Amersham, Piscat-
away, NJ) and utilized at the concentration recommended by the
manufacturer. Anti-ubiquitin and anti-vimentin antibodies for
immunofluorescence analysis were obtained from Santa Cruz
Biotechnology(SantaCruz,CA).Texasred-labeledgoatanti-mouse
Immunoglobulin G and Fluorescein-labeled horse anti-rabbit
Immunoglobulin G were obtained from Molecular Probes (Carls-
bad, CA), and Vector Laboratories (Burlingame, CA) respectively
and used at the concentration recommended by the manufacturer.
Cellular morphology and immuno-fluorescence analyses
A Nikon Eclipse TE 2000E inverted microscope was used for the
imaging of cellular morphology with phase contrast and immuno-
fluorescence. For analysis of ubiquitin and vimentin sub-cellular
localization, cultures of HeLa cells were grown as described in Lab-
TekII chambered coverglass(Nalge Nunc International, Rochester,
NY). At the indicated times, cells were fixed and permeabilized with
methanol and incubated with the indicated primary antibodies.
Fluorescent secondary antibodies were used to visualize protein
localization and nuclear DNA visualized by 4,6-diamidino-2-
phenylindole (DAPI) staining. Mounted samples were viewed under
a Nikon Eclipse TE 2000E inverted microscope and images
captured with Spot 3.5.8 acquisition software (Diagnostic Instru-
ments, Sterling Heights, MI).
Measurement of Proteasomal activity in 20S Purified
Proteasomes
Cells (5610
8) were washed in cold PBS and resuspended in
buffer containing 50 mM TRIS-HCl (pH 7.5), 5 mM MgCl2,
1 mM DTT (Sigma), 2 mM ATP and 250 mM sucrose. Glass
beads equivalent to the volume of the cell suspension were added,
and the mixture was vortexed for 1 min at 4uC. Beads and cell
debris were removed by 5 min centrifugation at 1,000 g, followed
by 20 min centrifugation at 10,000 g [27]. Lysates were cleared by
ultracentrifugation for 1 hr at 100,000 g, and supernatants were
further ultracentrifuged for 5 hr at 100,000 g. Proteasome-
containing pellets were resuspended in 0.5 ml of homogenization
buffer [50 mM TRIS-HCl (pH 7.5), 100 mM KCl, 15% glycerol].
Protein concentration was determined using the BCA protocol
(Pierce, Rockford, IL). Fluorogenic substrates Suc-LLVY-AMC,
Boc-LRR-AMC and Ac-YVAD-AMC were used to measure
chymotryptic-like, tryptic-like and caspase-like activities, respec-
tively. Semipurified proteasomes (10 ml), pretreated or not with
inhibitors for 30 min at 37uC, were assayed at 37uC for 45 min
using the different peptide substrates in a buffer containing 50 mM
TRIS-HCl (pH 7.5), 5 mM MgCl2 and 1 mM DTT (final volume
100 ml). The reaction was quenched with 1 ml 1% SDS and
fluorescence determined by fluorimeter (Perkin-Elmer, Beacons-
field, UK) with excitation at 380 nm and emission at 440 nm [18].
Data are expressed as the percent inhibition relative to untreated
proteasomal preparations.
Measurement of Proteasomal activity in 26S Proteasomes
in living cells
Exponentially growing cells (1610
6) were plated in 60 mm
dishes and either mock treated or treated with different
concentration RAMB1 over a period of 4 hours. Proteasomal
activity in cell lysates (NP-40 lysis buffer: 0.1% NP-40, 50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 5% glycerol and 1 mM DTT)
was determined by measuring residual luminescence activity
Causing UPS Stress for Cervical Cancer Treatment
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23888following addition of the Suc-LLVY-Glo
TM substrate (Promega,
Madison, WI) specific for the chymotrypsin-like activity of the
proteasome according to the manufacturer’s recommendations.
Assay of 4XUbiquitin-Luciferase degron
The 4Xubiquitin–luciferase fusion construct designated Ub-FL
and the control plasmid designed CMV-FL were kindly provided
by Dr. David Piwnica-Worms (Washington University, St. Louis,
MO) [26]. Sub-confluent cultures of HeLa cells were transfected
with plasmids DNA by using Lipofectamine 2000 reagent (Life
Technologies, Carlsbad, CA). FL and Ub-FL transfected HeLa
cells were seeded at 50,000 cells/well in 24-well plates or 200,000
cells/well in 6-wells plate 24 hours post transfection and incubated
with compounds or vehicle (DMSO) at the doses and times
indicated. Luciferase activity in cell lysate was determined with a
luciferase assay kit (Promega, Madison, WI) according to the
manufacturer’s instructions. Images were acquired for 1 min with
a Xenogen IVIS 200 (Caliper, Hopkinton, MA). Equally sized
areas were analyzed using Living Image 2.20 software.
Clonogenic assay
Exponentially growing SiHa, CaSki and HeLa cervical cancer
cells were seeded at either 1,000 or 100 cells/well in 6 well plates.
One day post seeding, the cells were treated with either vehicle
alone (mock) or RAMB1 at the indicated doses, and incubated at
37 C in 5% CO2 for 10 days. At the end of the treatment the
medium was removed and the cells were rinsed with PBS prior
fixation and staining of the colonies using a mixture of 6.0%
glutaraldehyde and 0.5% crystal violet as previously described
[27]. Colonies were imaged and counted using a Nikon Eclipse TE
2000E inverted microscope and images captured with Spot 3.5.8
acquisition software (Diagnostic Instruments, Sterling Heights,
MI). All the experiments were conducted in triplicate.
Statistical analysis
Results are reported as mean 6 Standard Deviation (SD).
Statistical significance of differences was assessed by two-tailed
Student’s t using Prism (V.5 Graphpad, San Diego, CA) and Excel.
The level of significance was set at p#0.05. The combination
index (CI) of RAMB1 and Chloroquine was calculated by the
median-effect analysis according to the method of Chou and
Talaly [28]. CI,1 indicates synergism, CI=1 indicates additivity,
and CI.1 indicates antagonism. Further regression analyses were
performed to stabilize estimates.
Results
RAMB compounds selectively reduce the viability of
cervical cancer cells independently of HPV genotype via
blockade of proteasomal degradation
Flavonoids and triterpenoids family members including celastrol
[19], resveratrol [29,30], curcumin [17], epigallocatechin-3-gallate
[20,31,32,33,34] and chalcones [35,36] exhibit anti-cancer
properties associated with their activity as proteasome inhibitors
[14,15,16,21]. We recently reported that in chalcone-based
proteasome inhibitors the nature of the aminoacid portion of the
molecule confers specificity toward catalytic activities of the 20S
proteasome [14]. Based upon several prior studies [22,23,37], we
hypothesized that the a-b ketone system of chalcones may
represent the minimum molecular determinant for inhibition of
ubiquitin-mediated protein degradation upstream of proteasomes.
To test this hypothesis we initially screened a library of
chalcone-based derivatives carrying various substituents on the
aromatic rings adjacent to the a-b ketone system and lacking
aminoacidic portions, for their cell growth inhibitory capacity in
exponentially growing HPV18-positive HeLa cervical cancer cell
line in a range of concentration from 100 to 0.01 mM (not shown).
Four chalcone derivatives, hereafter termed RAMBs, capable of
reducing the cell viability of exponentially growing HeLa cervical
cancer cells in a dose-dependent fashion with IC50 values ,5 mM,
were chosen for further evaluation (Figure 1). To determine the
feasibility of using RAMBs compounds for treatment of cervical
cancer, we tested whether RAMB1–4 treatment would specifically
hinder the cell viability of cervical cancer cells over normal
keratinocytes and whether the reduction in cell viability in cervical
cancer cells is dependent upon the HPV-genotype. As shown in
Figure 2, RAMB1 or RAMB4 treatment produced a dose-
dependent reduction in the viability of HPV16-positive SiHa and
Caski cells and HPV-39-positive ME180 cervical cancer cell lines
respectively with minimal effects on the viability of primary human
keratinocytes and with IC50 similar to the obtained with HeLa.
Similar results with slightly higher IC50 were obtained using
RAMB2 and RAMB3 (not shown). To test whether the reduction
in cell viability observed in cervical cancer cells following exposure
to the RAMB1–4 compounds was due to their capacity of interfere
with ubiquitin-mediated protein degradation, we monitored the
levels of accumulation of poly-ubiquitinated proteins following
treatment. Specifically, HeLa cells were treated with 5 mMo f
RAMB1, RAMB2, RAMB3, or RAMB4 or 10 nM of Bortezomib,
the latter being used as UPS-stressor positive control, over a period
of 6 hours. As shown in Figure 3 (left panel), immunoblot analysis of
ubiquitinated protein expression levels in HeLa cells revealed a
clear pattern of accumulation of poly-ubiquitinated proteins in
RAMBs -treated HeLa cultures. A semi-quantitative analysis of
the polyubiquitinated protein levels shows that the GAPDH-
normalized levels of polyubiquitinated proteins are consistently
higher (up to 3-fold) in RAMB-treated versus mock-treated cells
(Figure 3, right panel). These findings suggest that the decrease in
cell viability observed in the cervical cancer cell panel but not in
normal cells following RAMBs treatment is associated with the
perturbation of ubiquitin-mediated protein degradation and
occurs regardless of the oncogenic HPV type.
RAMB treatment triggers a Ubiquitin-Proteasome-System
(UPS)-stress response without affecting 20S proteasome
catalytic activities
To test whether the rapid (six hours or less, unpublished data)
accumulation of poly-ubiquitinated proteins following RAMBs
exposure occurs concomitantly with direct inhibition of the
Figure 1. Summary of the structure of compounds RAMB1–4
and their IC50 values in HeLa cervical cancer cell line. IC50 values
were determined by XXT assay. The IC50 value reported are average of
three independent determinations.
doi:10.1371/journal.pone.0023888.g001
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RAMB1 and RAMB4 (which induced a greater accumulation of
polyubiquitinated protein than the other RAMBs, Figure 3) to
inhibit specific catalytic sub-units within the 20S proteasome.
Specifically the RAMBs were tested for their capacities to inhibit
the chymotrypsin-like (CT-like), trypsin-like (T-like) and peptidyl-
glutamyl peptide hydrolyzing-like (PGPH-like) activities in 20S
purified proteasome pre-exposed to escalating doses up to 10 mM
of RAMBs for a period of 30 minutes following addition of
fluorogenic substrates [38]. The FDA licensed proteasome
inhibitor Bortezomib was used as positive control. As shown in
Figure 4 the profile of proteasome inhibition shows that unlike
Bortezomib, RAMB1 and RAMB4 treatment failed to inhibit
proteasomal functions when tested to concentrations up to 10 mM
(similar results were obtained with the other compounds of the
series, not shown).
In order to assess whether the failure to inhibit proteasomal
function in vitro can be recapitulated in the intact proteasome
found in living cells, we utilized two different approaches. First, we
utilized the ubiquitin-luciferase bioluminescent reporter 4XUb-
FL, which resists cleavage by ubiquitin hydrolases [26], to transfect
HeLa cells. Using Ub-FL and FL transfected HeLa cells we have
monitored luciferase activity following exposure to RAMBs over a
period of 6 hours. As shown in Figure 5 (left) unlike Bortezomib or
our recently identified proteasome inhibitor RA1 [14], here used
as proteasome inhibitors positive controls, RAMB1 or RAMB4
treatment induced a weaker stabilization of the Ub-FL reporter
when tested at concentration up to 20 mM than seen for either
RA-1 or Bortezomib. Quantification of Ub-FL/FL ratio in mock
versus RAMBs exposed culture is provided in Figure 5 (middle
panel). Next, the lack of inhibition of 20S proteasomal activity in
RAMB-treated cells was confirmed by measuring the residual
fluorogenic activity in 20S proteasome purified from CaSki
cervical cancer cells pre-exposed to RAMB1 or RAMB4 for
4 hours. As shown in Figure 5 (right panel), unlike Bortezomib,
RAMB1 treatment failed to inhibit the chymotryptic activity of
proteasomes when tested to concentrations up to 20 mM. Taken
together, this suggests that the loss of cell viability in cervical
Figure 2. Effect of RAMB treatment upon cervical cancer cell lines and primary human keratinocytes. Cultures of HPV-transformed
cervical cancer cells (SiHa, CaSki and ME180) or primary human keratinocytes were treated with the indicated concentrations of RAMB1 (left panel)o r
RAMB4 (right panel) over a period of 48 hours. Cell viability was determined by XTT assay and plotted as a fraction of the untreated control cultures.
doi:10.1371/journal.pone.0023888.g002
Figure 3. Effects of RAMB treatment on the levels of polyubiquitinated proteins in HeLa cells. Left panel: immunoblot analysis of
ubiquitinated proteins in HeLa cells after 6 hours exposure with or without 10 mM RAMBs. Bortezomib was used as positive control. Equal protein
loading in each lane was verified by using an antibody against GAPDH. Right panel: Quantification of the Ubiquitin/GAPDH ratios.
doi:10.1371/journal.pone.0023888.g003
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the accumulation of polyubiquitated proteins without the direct
inhibition of 20S proteasomal activity.
RAMB1 treatment induces aggresome formation and
triggers heat-shock responses
We and others have shown that inhibition of ubiquitin-mediated
protein degradation via proteasomal inhibition triggers heat-shock
and unfolded protein responses including formation of cytopro-
tective structures called aggresomes as a mechanism to compen-
sate for inhibition of proteasomal functions and increasing levels of
UPS stress within cancer cells [4,6,39]. To test whether the rapid
accumulation of poly-ubiquitinated protein upon RAMB1 treat-
ment occurs concomitantly with heat-shock protein responses
(UPR) we monitored the protein expression levels of Hsp90 in
HeLa cervical cancer cells exposed to 10 mM RAMB1–3 for
8 hours. As shown in Figure 6A (left panel) immunoblot analysis of
Hsp90 protein expression levels revealed that a strong pattern of
accumulation of Hsp90 in RAMB1-treated versus mock-treated
HeLa cell cultures (similar results were obtained with the other
derivative of the series, not shown). A semi quantitative analysis of
the Hsp90 protein levels show that the GAPDH-normalized levels
of polyubiquitinated proteins are nearly 2-fold higher in treated
versus non-treated cells is shown in Figure 6A (right panel).
Next, we hypothesized that accumulation of poly-ubiquitinated
proteins following RAMB compound exposure would lead to
activation of alternative compensatory pathways to ubiquitin-
mediated protein degradation, specifically to lysosomal pathway
activation. To test this hypothesis we monitored the sub-cellular
localization of ubiquitin by immunofluorescence microscopy
analysis in HeLa cervical cancer cells exposed to 10 mMo f
RAMB1. As shown in Figure 6B immunofluorescence analysis of
poly-ubiquitinated proteins in HeLa cells treated with RAMB1
reveals the presence of vimentin-caged, ubiquitin-positive, aggre-
somes structure consistent with that previously described upon
treatment with Bortezomib [6]. Taken together, these findings
indicate that in RAMB1-treated cells the accumulation of poly-
ubiquitinated results in similar cytoprotective responses as
inhibition of proteasome catalytic activities by Bortezomib, but
occurs through a mechanism independent from it.
RAMB1 treatment leads to p53 stabilization, cyclin D1
destabilization and onset of apoptosis
The E6 oncoprotein of HPV exerts its oncogenic activity by
targeting p53 and other tumor suppressor proteins for rapid
ubiquitin-mediated proteasomal degradation. This reduces the
level of this key cellular cell cycle regulator without mutation of
p53. To test whether the impairment of ubiquitin-mediated
protein degradation following RAMBs treatment leads to
stabilization of p53 as a potentially contributing mechanism
initiating cell death, we examined the expression levels of p53
following 6 hours exposure to compounds 10 mM of RAMBs. As
Figure 4. RAMB treatment fails to inhibit the 20S proteasome proteolytic activities. Purified 20S proteasomes were treated for 30 min
with or without RAMB compounds or Bortezomib, here used as positive control, at the indicated concentrations and the specific fluorogenic
substrates for chymotrypsin-like, trypsin-like and peptidylglutamyl peptide hydrolyzing-like hydrolytic proteasome capacities were subsequently
added. A representative example of two independent experiments is shown.
doi:10.1371/journal.pone.0023888.g004
Figure 5. RAMB treatment fails to inhibit proteasomal activity in living cells. Left panel: Luciferase activity in lysates of Ub-FL or FL-vector
transfected cells either with or without treatment with RAMB compounds or Bortezomib were quantified in Relative Luminescence Units (RLU) and
expressed as % of control. Error bars are Standard Deviation (SD) for three independent experiments. Middle panel: Quantification of the Ub-FL/FL
ratio. Right panel: Luminescence activity in cell lysates derived from CaSki cervical cancer cells with or without RAMB or Botezomib treatment
quantified in Relative Luminescence Units (RLUs). *, P,0.05, **, P,0.02.
doi:10.1371/journal.pone.0023888.g005
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dose-dependent accumulation of p53 in CaSki cervical cancer cells
as compared to mock control. Importantly, p53 stabilization
causes suppression of cyclin D1 promoter resulting in active
repression of cyclin D1 transcription [40]. To test whether this
results in reduction of cyclin D1 expression levels, CaSki cervical
cancer cells were exposed to increasing doses of RAMB1 over a
period up to 8 hours. As shown in Figure 7B (left panel) RAMB1
treatment causes time-dependent (top) and dose-dependent (bottom)
decrease of cyclin D1 levels suggesting failure of cervical cancer to
enter the S- phase of the cell cycle as a cause of cell toxicity [41]. A
semi quantitative analysis of b-actin-normalized cyclin D1 levels is
given in Figure 7B (right panel top and bottom).
To test whether this results in reduction of cyclin D1 expression
levels, CaSki cervical cancer cells were exposed to increasing doses
of RAMB1 over a period up to 8 hours. A semi quantitative
analysis of b-actin-normalized cyclin D1 levels is given in Figure 7B
(right panel top and bottom). As shown in Figure 7B (left panel) RAMB1
treatment causes very rapid (top) and dose-dependent (bottom)
decrease of cyclin D1 levels suggesting failure of cervical cancer to
enter the S-phase of the cell cycle may contribute to the loss of cell
viability [41].
Stabilization of p53 steady-state levels and destabilization of
cyclin D1 levels suggest that the reduction in cell viability observed
in the panel of cervical cancer cells following RAMBs exposure
might trigger the onset of apoptosis. To test this hypothesis, HeLa
cervical cancer cells were exposed to 5 mM of RAMB1 and
analyzed by flow cytometry after staining for annexin V binding
and 7-AAD incorporation. Annexin V and 7-AAD staining allows
to discriminate viable (annexin V
neg/7-AAD
neg), apoptotic (an-
nexin V
pos/7-AAD
neg), and dead (annexin V
pos/7-AAD
pos) cells.
As shown in Figure 7C (left panel), 24 hr exposure to RAMB1
caused an increase in both the early (annexin V positive
population) and late (annexin V and 7-AAD double positive
population) and apoptotic population in treated cultures versus
controls. To evaluate whether this is due to caspase activation, we
measured the levels of PARP cleavage in HeLa cancer cells
following exposure to RAMB1. As shown in Figure 7C (middle
panel), higher levels of cleaved PARP are apparent in treated versus
untreated cultures indicating caspase-3 activation. Quantification
of the cleaved PARP/GAPDH is provided in Figure 7C (right
panel). These findings support our hypothesis that RAMBs
treatment triggers apoptosis in cervical cancer cells.
RAMB1 treatment prevents anchorage-dependent
tumor-colony formation of cervical cancer cells and
synergizes with the lysosome inhibitor Chloroquine
A hallmark of cancer cells is their capacity to form colonies in
vitro that is indicative of the loss of contact inhibition typical of
normal cells. To test the potential of RAMB1 as a therapeutic
agent for cervical cancer, we have examined the effects of RAMB1
treatment on the anchorage-dependent growth of SiHa, CaSki
and HeLa cervical cancer cell lines. Specifically, SiHa and CaSki
cancer cells were either mock treated or treated with escalating
doses of RAMB1 over a period of 10 days and their ability to form
colonies was evaluated by crystal violet staining. As shown in
Figure 8A, RAMB1 exposure resulted in a dose-dependent
inhibition of colony formation by SiHa and CaSki cervical cancer
Figure 6. RAMB treatment induces accumulation of Hsp90 and aggresomes. A. Left panel: immunoblot analysis of Hsp90 expression levels
in HeLa cervical cancer cells after 8 hours exposure with or without 10 mM RAMBs treatment. Bortezomib was used as positive control. Equal protein
loading in each lane was verified by using an antibody against GAPDH. Right panel: Quantification of the Hsp90/GAPDH ratio. B. HeLa cells were
incubated with or without 5 mM RAMB1 or 10 nM Bortezomib for 18 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin
(green) and vimentin (red) before imaging (606).
doi:10.1371/journal.pone.0023888.g006
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concentrations as low as 0.62 mM.
We next quantified the impact of RAMB1 treatment on the
reductionofcolonynumberand sizein1610
2 HeLacervical cancer
cells treated with or without 0.15 or 0.5 mM RAMB1. As shown in
Figure 8B (left panel) RAMB1 exposure resulted in 40% and 60%
reduction in colony number when exposed to 0.15 or 0.3 mM
RAMB1 respectively. RAMB1 treatment also resulted in 50% and
80% reduction in colony size in mock versus RAMB1 treated HeLa
cells as shown in Figure 8B (middle panel). A representative example
of crystal violet staining in HeLa cervical cancer cells following
RAMB1 exposure is given in Figure 8B (right panel).
The increase in the steady-levels of Hsp90 and formation of
aggresome-like structure following RAMB1 treatment suggest
compensatory activation of lysosomal pathway of protein degrada-
tion (Fig. 6). Therefore, we hypothesized that RAMB1 treatment
would result in synergistic cell killing when combined with an
inhibitor of this lysosomal pathway. To test this hypothesis, we
compared the effect of combined treatment with RAMB1 and the
lysosome inhibitor Chloroquine on the viability of HeLa cervical
cancer cells. Consistent with our hypothesis, submaximal doses of
RAMB1 and Chloroquine act synergistically to cause enhanced
cytotoxicity in HeLa cervical cancer cells with a Combination Index
(CI) of 0.48 observed using 1.45 mM RAMB1 and 7.23 mM
Chloroquine (Figure 7C). Similar results were obtained with SiHa
and CaSki cell lines (data not shown). Taken together, this suggest
that the combinatorial approach of inhibiting ubiquitin-dependent
proteindegradationupstreamofproteasomeand lysosomalpathway
could lead to development of combination therapeutic strategies
where the side effects of each individual compounds can be reduced
without compromising the anti-cancer activity of the treatments.
Discussion
Numerous naturally-derived compounds are either FDA
approved or currently under evaluation for the treatment of
human malignances. Among these natural compounds with
Figure 7. Stabilization of p53, reduction in cyclin D1 and onset of apoptosis following RAMB1 treatment. A. Immunoblot analysis of
p53 expression level in CaSki cells treated with the indicated concentration of RAMB1 over a period of 8 hours. Equal loading is each lane was verified
by amido black staining. B. Top left panel: Immunoblot analysis of cyclin D1 expression level in CaSki cells with or without 10 mM RAMB1 for a period
up to 8 hours. Protein loading was examined using an antibody against b-actin. Top right panel: Quantification of the cyclin D1/b-actin ratio. Bottom
left panel: Immunoblot analysis of cyclin D1 expression level in CaSki cells with or without RAMB1, at the indicated concentration for a period of
8 hours. Equal protein loading in each lane was verified by using an antibody against b-actin. Bottom right panel: Quantification of the cyclin D1/b-
actin ratio. C. Left panel. HeLa cells were treated with 10 mM of RAMB1 for 8 hours and analyzed by flow cytometry after staining for annexin V
binding and 7-AAD incorporation. Middle panel: Immunoblot analysis of full length and cleaved PARP in HeLa cells treated 10 mM of RAMBs over a
period of 8 hours. Protein loading was assessed using an antibody against b-actin. Right panel: Quantification of cleaved PARP/b-actin ratio.
doi:10.1371/journal.pone.0023888.g007
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triterpene families. While the chemical common denominator
within these two families capable of inducing preferential killing in
cancer cells is yet to be identified, a number of studies support the
idea that they share an ability to inhibit one or multiple catalytic
activities of the proteasome, and that their anti-cancer activities
stems from this inhibition [14,15,17,21].
While we have recently shown that in chalcone-based small
molecule inhibitors of proteasome the nature of aminoacidic
component determines the selectivity toward individual catalytic
activities of the proteasome [14], a substantial body of evidence
indicates that chalcones may have within their b-carbons to a,b-
unsaturated carbonyls the molecular determinant for inhibition of
ubiquitin-dependent protein degradation upstream of proteasomes
[22,23,24,25]. Thus, they may exert anticancer activity by
induction of UPS stress via a mechanism independent from direct
inhibition of the catalytic activities of the 20S proteasome.
Given these observations and based on our recent work [14], we
have synthesized a library of chalcone-based small molecules
(RAMBs) containing a,b-unsaturated carbonyl systems and
lacking aminoacid substitutions and tested their antineoplastic
potential via inhibition of ubiquitin-mediated protein degradation
Figure 8. RAMB1 treatment prevents anchorage-dependent colony formation and synergizes with Chloroquine to kill cervical
cancer cells. A. Equal numbers of SiHa and Caski cells (10
3) were seeded into 6-wells plastic dishes and treated with or without RAMB1 at the
indicated concentrations over a period of 10 days. Colonies were visualized by crystal violet staining. B. Left panel: Quantification of colony number in
mock versus RAMB1 treated HeLa cells. Middle panel: Quantification of colony size in mock versus RAMB1 treated cervical cancer cells. Right panel:
Representative experiment of HeLa cells (10
2) which were seeded into 6-wells plastic dishes and treated with or without RAMB1 at the indicated
concentration over a period of 10 days. Colonies were visualized by crystal violet staining and manually counted using an inverted microscope.
Inserts: Representative example of colony size in mock versus RAMB1-treated cells. Middle panel: Quantification of colony number. Right panel:
Quantification of colony size, representative of three independent experiments. **, P,0.02. C. CaSki cells were treated with checkerboard dilution
series of RAMB1 and Chloroquine over a period of 24 hours. Cell viability was measured by XTT assay and calculated as percent of control untreated
cultures. Synergy is expressed as combination index (CI).
doi:10.1371/journal.pone.0023888.g008
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show that, when probed for their capacity to interfere with
degradation of poly-ubiquitinated proteins, RAMB treatment is
associated with increased levels of poly-ubiquitinated proteins
(occurring as early as two hours from exposure) but unaltered 20S
proteasomal catalytic activity when tested in vitro and in living cells.
Notably, while not statistically significant, RAMB1 treatment led
to some stabilization of the Ub-FL degron. This may reflect a
feedback inhibition of proteasome function due to increasing levels
of poly-ubiquitinated protein content in RAMB1 exposed cultures.
Importantly, when tested against a panel of cervical cancer cell
lines versus keratinocytes, RAMBs showed a preferential killing for
the malignant versus the normal phenotype. This appears to be
consistent with the notion that due to their endogenously high levels
of UPS stress cancer cells are more sensitive than normal cells to
perturbation of ubiquitin-mediated protein degradation [4].
Activation of p53 via its stabilization is a potential therapeutic
approach for treatment of those cancers, including cervical cancer,
expressing wild-type p53. E6 oncoprotein transforms cervical
cancer cells by targeting p53 for ubiquitin-dependent proteasomal
degradation resulting in reduction of the levels of this and other
tumor-suppressor proteins. Therefore, stabilization of p53 by
preventing its degradation could recover sufficient levels of wild-
type p53 to trigger apoptotic cell death as a response to the
abnormal growth of the cancer cell. We show here that RAMB1
treatment causes dose-dependent accumulation/stabilization of
p53. Because stabilization of the levels of p53 occurs concomi-
tantly with accumulation of high-molecular weight poly-ubiquiti-
nated species and as early as 2 hours post-treatment (well before
cell death is observed, not shown), this suggests that stabilization of
p53 is the cause rather then the consequence of the decrease in cell
viability in cervical cancer cells. Induction of p53 via stabilization
of its steady state levels correlates with decrease in the levels of
cyclin D1 possibly via repression of its transcription [40]. RAMB1
treatment also results in a dose- and time-dependent reduction in
the steady state levels of cyclin D1 which could at least partially
account for the decrease in cell viability observed in the cervical
cancer cell lines. Interestingly, because the decrease in the cyclin
D1 expression levels are seen as early as 30 minutes following
RAMB1 exposure and before detectable stabilization of p53
expression levels, it is possible that cyclin D1 down-regulation is
occurring in response to UPS stress rather to p53 activity. In this
scenario an arrest in S-phase would precede the onset of apoptosis
in RAMBs exposed cervical cancer cells as confirmed by Annexin
V staining and PARP-cleavage. This is likely the same mechanism
responsible for reduction in colony number observed in the panel
of cervical cancer cell lines exposed to RAMB1 treatment.
Interestingly, because the reduction in colony number is
accompanied by reduction in colony size we conclude that
RAMB1 has an effect in slowing the proliferation rate of cervical
cancer cells that are initially resistant to its action.
Inhibition of conventional (proteasomal-mediated) ubiquitin-
dependent protein degradation triggers activation of alternative
pathways to proteasomal degradation as a mechanism to
compensate for abnormally increased levels of UPS stress. The
increase in the levels of poly-ubiquitinated proteins following
RAMB1 exposure corresponds to their sub-cellular localization in
vimentin-encaged structures consistent with the formation of
aggresomes and occurs concomitantly with up-regulation of Hsp90
protein expression levels. This indicates activation of the lysosomal
protein degradation pathway as an attempt to ‘‘isolate’’ mis-folded
and oxidized proteins and subsequent recycling of the aggresomes
via autophagy to cope with increasing levels of UPS stress [6,39].
In this scenario we show that a combinatorial approach of using
RAMB1 and the lysosome inhibitor Chloroquine reduce the
viability of cervical cancer cells significantly better than either
treatment alone. This synergism presumably reflects blockade of
the proteasomal and compensatory lysosomal degradation path-
ways by RAMB1 and Chloroquine respectively, and provides a
rational to further explore this new therapeutic approach for the
treatment of cervical cancer.
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